These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11728615)

  • 1. Characteristics of fluvoxamine-induced nausea.
    Ueda N; Yoshimura R; Shinkai K; Terao T; Nakamura J
    Psychiatry Res; 2001 Nov; 104(3):259-64. PubMed ID: 11728615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher plasma 5-hydroxyindoleacetic acid levels are associated with SSRI-induced nausea.
    Ueda N; Yoshimura R; Shinkai K; Sakata Y; Nakamura J
    Neuropsychobiology; 2003; 48(1):31-4. PubMed ID: 12886038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-HT3 receptors, nausea, and serotonin reuptake inhibition.
    Coupland NJ; Bailey JE; Potokar JP; Nutt DJ
    J Clin Psychopharmacol; 1997 Apr; 17(2):142-3. PubMed ID: 10950495
    [No Abstract]   [Full Text] [Related]  

  • 4. A display of hypomania in a depressed male in response to fluvoxamine.
    Horiguchi T; Sai S
    World J Biol Psychiatry; 2001 Oct; 2(4):201-4. PubMed ID: 12587152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment.
    Takahashi H; Yoshida K; Ito K; Sato K; Kamata M; Higuchi H; Shimizu T; Ito K; Inoue K; Tezuka T; Suzuki T; Ohkubo T; Sugawara K
    Eur Neuropsychopharmacol; 2002 Oct; 12(5):477-81. PubMed ID: 12208565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mild case of serotonin syndrome?
    McIntosh D
    Can J Psychiatry; 2000 Aug; 45(6):571-2. PubMed ID: 10986578
    [No Abstract]   [Full Text] [Related]  

  • 7. Neuroleptic malignant syndrome induced by quetiapine and fluvoxamine.
    Matsumoto R; Kitabayashi Y; Nakatomi Y; Tsuchida H; Fukui K
    Am J Psychiatry; 2005 Apr; 162(4):812. PubMed ID: 15800166
    [No Abstract]   [Full Text] [Related]  

  • 8. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation.
    Bondolfi G; Chautems C; Rochat B; Bertschy G; Baumann P
    Psychopharmacology (Berl); 1996 Dec; 128(4):421-5. PubMed ID: 8986013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mirtazapine for treatment of nausea induced by selective serotonin reuptake inhibitors.
    Caldis EV; Gair RD
    Can J Psychiatry; 2004 Oct; 49(10):707. PubMed ID: 15560319
    [No Abstract]   [Full Text] [Related]  

  • 10. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.
    Gerstenberg G; Aoshima T; Fukasawa T; Yoshida K; Takahashi H; Higuchi H; Murata Y; Shimoyama R; Ohkubo T; Shimizu T; Otani K
    Psychopharmacology (Berl); 2003 Jun; 167(4):443-8. PubMed ID: 12682708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlated reductions in cerebrospinal fluid 5-HIAA and MHPG concentrations after treatment with selective serotonin reuptake inhibitors.
    Sheline Y; Bardgett ME; Csernansky JG
    J Clin Psychopharmacol; 1997 Feb; 17(1):11-4. PubMed ID: 9004051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine.
    Yoshida K; Naito S; Takahashi H; Sato K; Ito K; Kamata M; Higuchi H; Shimizu T; Itoh K; Inoue K; Suzuki T; Ohkubo T
    Neuropsychobiology; 2003; 48(1):10-3. PubMed ID: 12886034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression.
    Ueda N; Yoshimura R; Shinkai K; Nakamura J
    Pharmacopsychiatry; 2002 Sep; 35(5):175-81. PubMed ID: 12237788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder.
    Hollander E; Koran LM; Goodman WK; Greist JH; Ninan PT; Yang H; Li D; Barbato LM
    J Clin Psychiatry; 2003 Jun; 64(6):640-7. PubMed ID: 12823077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression.
    Zanardi R; Serretti A; Rossini D; Franchini L; Cusin C; Lattuada E; Dotoli D; Smeraldi E
    Biol Psychiatry; 2001 Sep; 50(5):323-30. PubMed ID: 11543734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved outcome in fluvoxamine-treated patients with SSRI-induced sexual dysfunction.
    Banov MD
    J Clin Psychiatry; 1999 Dec; 60(12):866-8. PubMed ID: 10665636
    [No Abstract]   [Full Text] [Related]  

  • 17. Complex movement disorder associated with fluvoxamine.
    Bronner IM; Vanneste JA
    Mov Disord; 1998 Sep; 13(5):848-50. PubMed ID: 9756160
    [No Abstract]   [Full Text] [Related]  

  • 18. Violent acts associated with fluvoxamine treatment.
    Okada F; Okajima K
    J Psychiatry Neurosci; 2001 Sep; 26(4):339-40. PubMed ID: 11590975
    [No Abstract]   [Full Text] [Related]  

  • 19. Day/night variation of 5-hydroxyindole acetic acid concentration in rat cerebrospinal fluid after acute and long-term administration of a selective serotonin reuptake inhibitor, fluvoxamine.
    Egashira T; Takayama F; Yamanaka Y; Takada K; Takeda H; Matsumiya T
    Jpn J Pharmacol; 2000 Aug; 83(4):344-7. PubMed ID: 11001181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin syndrome induced by fluvoxamine and oxycodone.
    Karunatilake H; Buckley NA
    Ann Pharmacother; 2006 Jan; 40(1):155-7. PubMed ID: 16368927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.